logo
Aid groups warn of attacks on Sudan's hospitals as disease outbreaks and atrocities mount

Aid groups warn of attacks on Sudan's hospitals as disease outbreaks and atrocities mount

Yahoo4 days ago
CAIRO (AP) — Humanitarian organizations are sounding the alarm over attacks on healthcare facilities across Sudan, warning that they are happening amid what they describe as ongoing mass atrocities against civilians.
Doctors without Borders — also known as Médecins Sans Frontières or MSF — said Thursday that 70% of medical facilities in Sudan have either closed or are barely operational with no end to the war in sight.
Sudan's civil war broke out in April 2023 after simmering tensions between the Sudanese army and its paramilitary Rapid Support Forces (RSF), escalated to fighting across the country. Some 40,000 people have been killed and nearly 13 million displaced, including to other countries, according to U.N. agencies. War has left many facing food insecurity and risk of famine and exposure to disease outbreaks like cholera, which remains hard to contain due to Sudan's collapsed healthcare system.
In a report released Thursday titled 'Besieged, Attacked, Starved', MSF warned that access to healthcare is nearly impossible due to systematic attacks, while the remaining operational facilities remain under constant threat.
'We call to all warring parties to stop violence against the civilian health facilities and civilian infrastructure and to facilitate a large-scale humanitarian response,' said Michel-Olivier Lacharité, MSF's head of emergency operations in a news conference presenting the report.
Echoing MSF's concerns, Save the Children, warned Thursday that attacks on hospitals nearly tripled after two years of war. The group said in a statement that at least 933 people, including children, were killed during the first half of 2025.
This figure is a 60-fold increase over the deaths recorded during the same period of the previous year, according to the group. Those killed were either seeking medical care or accompanying a loved one in a hospital.
Major hospitals, clinics, health facilities, ambulances and medical convoys all saw fatal attacks in a country where half the population requires humanitarian assistance, according to Save the Children.
'We are concerned that in most cases, the hospitals that have come under fire also happen to be the only remaining hospitals in those areas, putting healthcare out of reach for millions, including displaced people,' said Francesco Lanino, deputy country director of programs and operations for Save the Children in Sudan.
MSF particularly warned against violence in El Fasher city, the capital of North Darfur province, that made it near impossible for residents there and nearby displacement camps to access healthcare.
As of April, only one hospital with surgical capacity remained partially operational, serving an estimated population of over one million. Over the past year, many patients and their caretakers have been killed while inside an MSF-supported medical facility.
MSF urged the warring parties to 'halt indiscriminate and ethnically targeted violence and facilitate an immediate large-scale humanitarian response', particularly referring to threats of attacks on the hundreds of thousands of people in El Fasher, where fighting intensified since May 2024.
Last month, Sudan's military accepted a U.N. proposal for a week-long ceasefire in El Fasher to allow aid delivery. However, the RSF did not explicitly agree to the truce and engaged in renewed clashes with the army in the southern part of the city this week.
MSF urged the international community — especially countries engaging with both the Sudanese army and the RSF — to take stronger action to address the crisis in Sudan.
'They must use all the leverage to prevent further mass atrocities. They must place protection of civilians at the core of their engagement with the warring parties,' said Christopher Lockyear, secretary general of MSF International, on Thursday.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

T2D Tied to Mortality in Both Ischemic and Nonischemic HF
T2D Tied to Mortality in Both Ischemic and Nonischemic HF

Medscape

time40 minutes ago

  • Medscape

T2D Tied to Mortality in Both Ischemic and Nonischemic HF

TOPLINE: Patients with type 2 diabetes (T2D) had approximately 20%-26% higher mortality rates following ischemic and nonischemic heart failure (HF) than those without diabetes, with similar patterns observed in both women and men. METHODOLOGY: Most epidemiologic studies assessing mortality risk in individuals with HF, categorized by etiology and diabetes status, have relied on clinical trials or hospital data, limiting their generalizability to the broader population. Researchers conducted an observational retrospective cohort study using primary care and hospital data from England to examine the association between T2D and all-cause mortality in patients with ischemic or nonischemic HF. Patients with newly diagnosed T2D were matched with up to four people without diabetes on the basis of sex, birth year, and general practice. Incident HF events were defined as ischemic if they followed an ischemic heart disease event after the diagnosis of T2D; otherwise, they were classified as nonischemic. The outcome of interest was all-cause mortality. A total of 73,344 patients with HF were included, of whom 18,296 had ischemic HF and 55,048 had nonischemic HF. Among patients with ischemic HF, 2806 women (mean age, 77.26 years) and 4447 men (mean age, 73.44 years) had T2D, whereas among those with nonischemic HF, 10,094 women (mean age, 78.33 years) and 9964 men (mean age, 74.83 years) had T2D. TAKEAWAY: During a median follow-up of 2.19 years for ischemic HF and 1.98 years for nonischemic HF, mortality was observed in 52.4% and 57.8% of patients, respectively. Age-standardized mortality rates following ischemic HF were higher in patients with T2D than in those without diabetes (19.2 vs 15.1 and 20.4 vs 16.5 per 100 person-years in women and men, respectively), with similar findings following nonischemic HF in women and men. T2D was associated with higher mortality rates following ischemic HF, with rates 26% higher in women (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.17-1.36) and 23% higher in men (aHR, 1.23; 95% CI, 1.15-1.31). Similarly, following nonischemic HF, T2D was associated with higher mortality rates in both women (aHR, 1.24; 95% CI, 1.19-1.29) and men (aHR, 1.20; 95% CI, 1.15-1.25). IN PRACTICE: 'This [study] highlights the ongoing need to optimize the prevention and management strategies in the overall population of individuals with type 2 diabetes and HF to reduce the risk of premature mortality,' the authors of the study wrote. SOURCE: This study was led by Kajal Panchal, MSc, Leicester Diabetes Centre, University of Leicester, Leicester, England, and was published online in Diabetes, Obesity and Metabolism. LIMITATIONS: This study relied on health records that were collected routinely, which may have introduced measurement errors for certain covariates. The lack of data on echocardiography prevented distinguishing between HF with preserved or reduced ejection fraction. Additionally, confounding variables, such as body fat distribution, dietary factors, and physical activity, were either unavailable or poorly recorded in the databases. DISCLOSURES: This study was funded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration East Midlands. Some authors reported being supported by the funding agency and NIHR Leicester Biomedical Research Centre. One author reported receiving consultancy fees, and another author reported being a consultant or speaker and receiving research grants from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

I'm a gastroenterologist. Here's why I tell my patients to eat this one fruit.
I'm a gastroenterologist. Here's why I tell my patients to eat this one fruit.

Washington Post

timean hour ago

  • Washington Post

I'm a gastroenterologist. Here's why I tell my patients to eat this one fruit.

Is there something I can eat to help with constipation? A lot of high-fiber foods and supplements make me bloated, but I don't want to take a laxative. I get this question often in my gastroenterology clinic. Gut symptoms like bloating and constipation are incredibly common, affecting up to a third of the population. Many people don't want to take medication if there are more natural ways to help. But I also know that simply recommending people increase their fiber intake is vague and not always useful.

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

Associated Press

timean hour ago

  • Associated Press

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

NanoViricides, Inc. (NYSE Amer.: NNVC), a clinical-stage biopharmaceutical company and a pioneer in broad-spectrum antivirals, announced today its accelerated plans to advance its lead drug candidate, NV-387, into Phase II clinical trials for MPox. This strategic decision positions the company to potentially bring a much-needed antiviral to market faster, addressing a critical global health need while also paving the way for further pipeline development. NanoViricides highlighted several key reasons for prioritizing MPox as the first indication for NV-387's Phase II development, even with strong efficacy data in animal studies for other major viral threats like RSV, Influenza, and COVID. Strategic Advantages of the MPox Focus The company believes its focus on MPox offers significant advantages: Urgent Need and Timely Trial Completion: With a continuing MPox epidemic in the African Region, there's a pressing demand for effective treatments. This also facilitates patient recruitment, enabling a more rapid completion of the clinical trial. Cost-Effectiveness: Conducting clinical trials in the African Region is substantially more economical compared to the US or Europe, allowing NanoViricides to optimize its research budget. Validation of Animal Model Data: A successful Phase II trial for MPox in humans would validate the company's use of lethal challenge animal models. This is a critical point, as NanoViricides' animal studies have consistently shown NV-387 to be significantly superior to existing drugs across all tested infections. Strong Financial and Public Health Case: The recent failure of tecovirimat (Tpoxx) in MPox clinical trials creates a clear void in the US Strategic National Stockpile (SNS) for effective antivirals against orthopoxviruses like MPox and Smallpox. Both tecovirimat and brincidofovir (Tembexa), currently approved for Smallpox under the 'FDA Animal Rule,' have shown limitations. Brincidofovir failed due to liver toxicity, and tecovirimat demonstrated no superiority over standard care. NanoViricides believes NV-387 could become a crucial addition to the SNS, potentially securing substantial initial acquisition contracts. Addressing a Critical Vulnerability: Unlike small chemical drugs that viruses can readily escape through mutations, NanoViricides' host-mimetic nanomedicine technology is designed to make it difficult for viruses to develop resistance. This is particularly important for bioterrorism readiness, as manipulated forms of viruses like Smallpox could be engineered to resist conventional treatments. The company emphasizes the strong case for the US Department of Health and Human Services (HHS) to support NV-387 development for bioterrorism preparedness. Innovative Drug Delivery Adding to its strategic advantages, NV-387 will be administered as 'NV-387 Oral Gummies.' This soft solid formulation is designed to dissolve naturally in the oral cavity, eliminating the need for swallowing pills or capsules. This is a significant benefit for MPox patients who often suffer from painful oral lesions, making swallowing difficult. Addressing the Broader MPox Threat The ongoing MPox epidemic in the Democratic Republic of Congo (DRC) is driven by Clade 1a and the more transmissible Clade 1b subtypes, which have higher case fatality rates than the Clade 2b circulating in the Western world. While sporadic Clade 1 cases have been reported in the USA without further spread, the potential for a larger epidemic cannot be ignored. NanoViricides asserts that readiness with an effective drug against Clade 1 MPox is crucial for national health security. NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide™ class of drug candidates is based on technology and proprietary know-how from TheraCour Pharma, Inc. Other notable stocks to keep on top of radar include Summit Therapeutics (SMMT), Regulus Therapeutics (RGLS), Vigil Neuroscience (VIGL), Alaunos Therapeutics (TCRT), CervoMed Inc. (CRVO), Niagen Bioscience (NAGE) and Beam Therapeutics (BEAM). Source: Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of BURU or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated fifteen hundred dollars by a 3rd party EDM Media Consulting Group for content distribution services on nnvc or July 6th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. This analysis represents the opinion of the author based on publicly available information and should not be considered investment advice. Investors should conduct their own due diligence before making investment decisions. Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: [email protected] City: Frisco State: Texas Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store